活動性乾癬性関節炎におけるウパダシチニブ: UPJOINT 研究における最初の192名の有効性と安全性, 多施設協同観察研究
Rheumatol Ther. 2023;10(6):1503–1508 doi: 10.1007/s40744-023-00589-3
In the UPJOINT open label study, the proportion of patients with PsA, and an inadequate response to csDMARDs or bDMARDs, who achieved minimal disease activity with upadacitinib was in line with the results of previous studies at 24 weeks. No new safety signals were identified.